$593 Million is the total value of Rhenman & Partners Asset Management AB's 89 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 44.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | Celgene Corp | $17,407,000 | -14.5% | 151,000 | -17.0% | 2.94% | -50.3% |
| GILD | Sell | Gilead Sciences Inc | $15,603,000 | -19.7% | 159,000 | -22.9% | 2.63% | -53.3% |
| ESPR | Sell | Esperion Therapeutics Inc | $11,753,000 | +93.8% | 126,926 | -15.4% | 1.98% | +12.7% |
| REGN | Sell | Regeneron Pharmaceuticals Inc | $9,933,000 | +7.6% | 22,000 | -2.2% | 1.68% | -37.4% |
| MDVN | Sell | Medivation Inc | $8,906,000 | +26.5% | 69,000 | -2.4% | 1.50% | -26.4% |
| RCPT | Sell | Receptos Inc | $7,173,000 | +11.5% | 43,500 | -17.2% | 1.21% | -35.2% |
| ABC | Sell | AmerisourceBergen Corp | $4,319,000 | +19.8% | 38,000 | -5.0% | 0.73% | -30.3% |
| CLVS | Sell | Clovis Oncology Inc | $4,008,000 | -16.2% | 54,000 | -36.8% | 0.68% | -51.2% |
| ABMD | Sell | Abiomed Inc | $3,937,000 | +41.7% | 55,000 | -24.7% | 0.66% | -17.5% |
| THOR | Sell | Thoratec Corp | $3,644,000 | +22.0% | 87,000 | -5.4% | 0.61% | -29.0% |
| CLDX | Sell | Celldex Therapeutics Inc | $3,317,000 | +3.9% | 119,000 | -32.0% | 0.56% | -39.6% |
| ARIA | Sell | Ariad Pharmaceuticals Inc | $3,189,000 | +16.9% | 387,000 | -2.5% | 0.54% | -31.9% |
| TSRO | Sell | Tesaro Inc | $3,042,000 | +30.6% | 52,999 | -15.4% | 0.51% | -24.0% |
| ARRY | Sell | Array BioPharma Inc | $2,948,000 | +14.4% | 400,000 | -26.6% | 0.50% | -33.5% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $2,761,000 | -38.8% | 280,000 | -23.9% | 0.47% | -64.3% |
| CLDN | Sell | Celladon Corp | $2,274,000 | -40.6% | 120,053 | -38.7% | 0.38% | -65.5% |
| Exit | Mirati Therapeutics Inc | $0 | – | -45,388 | -100.0% | -0.24% | – | |
| PCYC | Exit | Pharmacyclics Inc | $0 | – | -18,500 | -100.0% | -0.66% | – |
| ORI | Exit | Omnicell Inc | $0 | – | -70,000 | -100.0% | -0.67% | – |
| Exit | Auxilium Pharmaceuticals Inc | $0 | – | -77,000 | -100.0% | -0.77% | – | |
| TMO | Exit | Thermo Fisher Scientific Inc | $0 | – | -22,000 | -100.0% | -0.80% | – |
| HTWR | Exit | Heartware Intl Inc | $0 | – | -38,000 | -100.0% | -0.81% | – |
| BDX | Exit | Becton Dickinson & Co | $0 | – | -20,142 | -100.0% | -0.81% | – |
| P103PS | Exit | NPS Pharmaceuticals Inc | $0 | – | -89,000 | -100.0% | -0.92% | – |
| SLXP | Exit | Salix Pharmaceutical Ltd | $0 | – | -38,000 | -100.0% | -1.27% | – |
| Exit | Catamaran Corp | $0 | – | -92,000 | -100.0% | -1.38% | – | |
| ANTM | Exit | Anthem Inc | $0 | – | -41,000 | -100.0% | -1.49% | – |
| F113PS | Exit | Covidien Plc | $0 | – | -57,000 | -100.0% | -1.69% | – |
| UTI | Exit | Universal Health Services Inc B | $0 | – | -61,000 | -100.0% | -1.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.